• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RasIns:活化Ras蛋白的基因编码胞内抗体。

RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins.

作者信息

Cetin Mehmet, Evenson William E, Gross Garrett G, Jalali-Yazdi Farzad, Krieger Daniel, Arnold Don, Takahashi Terry T, Roberts Richard W

机构信息

Department of Molecular and Computational Biology, University of Southern California, Los Angeles, CA 90089, USA.

Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA.

出版信息

J Mol Biol. 2017 Feb 17;429(4):562-573. doi: 10.1016/j.jmb.2016.11.008. Epub 2016 Nov 16.

DOI:10.1016/j.jmb.2016.11.008
PMID:27865780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5798998/
Abstract

K- and H-Ras are the most commonly mutated genes in human tumors and are critical for conferring and maintaining the oncogenic phenotype in tumors with poor prognoses. Here, we design genetically encoded antibody-like ligands (intrabodies) that recognize active, GTP-bound K- and H-Ras. These ligands, which use the 10th domain of human fibronectin as their scaffold, are stable inside the cells and when fused with a fluorescent protein label, the constitutively active G12V mutant H-Ras. Primary selection of ligands against Ras with mRNA display resulted in an intrabody (termed RasIn1) that binds with a K of 2.1μM to H-Ras(G12V) (GTP), excellent state selectivity, and remarkable specificity for K- and H-Ras. RasIn1 recognizes residues in the Switch I region of Ras, similar to Raf-RBD, and competes with Raf-RBD for binding. An affinity maturation selection based on RasIn1 resulted in RasIn2, which binds with a K of 120nM and also retains excellent state selectivity. Both of these intrabodies colocalize with H-Ras, K-Ras, and G12V mutants inside the cells, providing new potential tools to monitor and modulate Ras-mediated signaling. Finally, RasIn1 and Rasin2 both display selectivity for the G12V mutants as compared with wild-type Ras providing a potential route for mutant selective recognition of Ras.

摘要

K-Ras和H-Ras是人类肿瘤中最常见的突变基因,对于预后不良的肿瘤赋予并维持致癌表型至关重要。在此,我们设计了可识别活性、GTP结合型K-Ras和H-Ras的基因编码抗体样配体(胞内抗体)。这些以人纤连蛋白第10结构域为支架的配体,在细胞内稳定,当与荧光蛋白标签融合时,可标记组成型活性G12V突变体H-Ras。通过mRNA展示进行针对Ras的配体初步筛选,得到了一种胞内抗体(称为RasIn1),它以2.1μM的解离常数(K)与H-Ras(G12V)(GTP)结合,具有出色的状态选择性以及对K-Ras和H-Ras的显著特异性。RasIn1识别Ras开关I区域中的残基,类似于Raf-RBD,并与Raf-RBD竞争结合。基于RasIn1进行亲和力成熟筛选,得到了RasIn2,其结合解离常数为120nM,并且同样保留了出色的状态选择性。这两种胞内抗体在细胞内均与H-Ras、K-Ras及G12V突变体共定位,为监测和调节Ras介导的信号传导提供了新的潜在工具。最后,与野生型Ras相比,RasInl和Rasin2对G12V突变体均表现出选择性,为Ras的突变体选择性识别提供了一条潜在途径。

相似文献

1
RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins.RasIns:活化Ras蛋白的基因编码胞内抗体。
J Mol Biol. 2017 Feb 17;429(4):562-573. doi: 10.1016/j.jmb.2016.11.008. Epub 2016 Nov 16.
2
H, N backbone assignment and comparative analysis of the wild type and G12C, G12D, G12V mutants of K-Ras bound to GDP at physiological pH.在生理pH值下,对与GDP结合的K-Ras野生型以及G12C、G12D、G12V突变体进行H、N主链归属及比较分析。
Biomol NMR Assign. 2020 Apr;14(1):1-7. doi: 10.1007/s12104-019-09909-7. Epub 2019 Aug 29.
3
Characterization of a Ras mutant with identical GDP- and GTP-bound structures .具有相同GDP结合结构和GTP结合结构的Ras突变体的表征
Biochemistry. 2009 Dec 8;48(48):11449-57. doi: 10.1021/bi901479b.
4
High-frequency 94 GHz ENDOR characterization of the metal binding site in wild-type Ras x GDP and its oncogenic mutant G12V in frozen solution.野生型Ras x GDP及其致癌突变体G12V在冷冻溶液中金属结合位点的高频94 GHz电子核双共振表征。
Biochemistry. 2006 Jan 10;45(1):42-50. doi: 10.1021/bi051156k.
5
Selection of phage-displayed fab antibodies on the active conformation of ras yields a high affinity conformation-specific antibody preventing the binding of c-Raf kinase to Ras.基于Ras活性构象筛选噬菌体展示的Fab抗体可产生高亲和力的构象特异性抗体,该抗体可阻止c-Raf激酶与Ras结合。
FEBS Lett. 1999 Dec 10;463(1-2):115-20. doi: 10.1016/s0014-5793(99)01617-8.
6
Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants.H-和K-Ras致癌P环突变体中的独特动力学和相互作用模式。
Proteins. 2017 Sep;85(9):1618-1632. doi: 10.1002/prot.25317. Epub 2017 May 31.
7
The structural basis for the transition from Ras-GTP to Ras-GDP.从Ras-GTP转变为Ras-GDP的结构基础。
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12138-42. doi: 10.1073/pnas.192453199. Epub 2002 Sep 4.
8
The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.Ras-RasGAP复合物:GTP酶激活的结构基础及其在致癌性Ras突变体中的丧失
Science. 1997 Jul 18;277(5324):333-8. doi: 10.1126/science.277.5324.333.
9
Guanosine triphosphatase stimulation of oncogenic Ras mutants.致癌性Ras突变体的鸟苷三磷酸酶刺激作用。
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7065-70. doi: 10.1073/pnas.96.12.7065.
10
DRoP: a water analysis program identifies Ras-GTP-specific pathway of communication between membrane-interacting regions and the active site.DRoP:一个水质分析程序可识别膜相互作用区域与活性位点之间 Ras-GTP 特异性通讯途径。
J Mol Biol. 2014 Feb 6;426(3):611-29. doi: 10.1016/j.jmb.2013.10.036. Epub 2013 Nov 2.

引用本文的文献

1
Using extension-based mRNA display to design antibody-like proteinogenic peptides for human PD-L1.利用基于延伸的mRNA展示技术设计针对人程序性死亡受体配体1(PD-L1)的类抗体蛋白质生成肽。
Protein Sci. 2025 Sep;34(9):e70268. doi: 10.1002/pro.70268.
2
Targeting Ras with protein engineering.利用蛋白质工程靶向 Ras。
Oncotarget. 2023 Jul 1;14:672-687. doi: 10.18632/oncotarget.28469.
3
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.靶向小分子 GTP 酶:KRAS 开创的针对先前无法控制的靶点的新兴方法。
Signal Transduct Target Ther. 2023 May 23;8(1):212. doi: 10.1038/s41392-023-01441-4.
4
Development and characterization of nanobodies that specifically target the oncogenic Phosphatase of Regenerating Liver-3 (PRL-3) and impact its interaction with a known binding partner, CNNM3.开发并鉴定能够特异性靶向致癌性肝再生磷酸酶-3(PRL-3)的纳米抗体,并影响其与已知结合伴侣 CNNM3 的相互作用。
PLoS One. 2023 May 23;18(5):e0285964. doi: 10.1371/journal.pone.0285964. eCollection 2023.
5
Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions.癌症免疫治疗中胞内抗体的治疗潜力:现状与未来方向
Antibodies (Basel). 2022 Jul 18;11(3):49. doi: 10.3390/antib11030049.
6
Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).化学酰化获得的丝氨酸可抑制 K-Ras(G12S)的致癌信号。
Nat Chem Biol. 2022 Nov;18(11):1177-1183. doi: 10.1038/s41589-022-01065-9. Epub 2022 Jul 21.
7
Engineering and exploiting synthetic allostery of NanoLuc luciferase.工程化与开发 NanoLuc 荧光素酶的人工别构调控。
Nat Commun. 2022 Feb 10;13(1):789. doi: 10.1038/s41467-022-28425-2.
8
Targeting the "undruggable" RAS with biologics.利用生物制剂靶向“不可成药的”RAS
Adv Cancer Res. 2022;153:237-266. doi: 10.1016/bs.acr.2021.07.006. Epub 2021 Aug 13.
9
Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma.工程化变异的 Ras 效应蛋白 RASSF5(NORE1A)可促进肺腺癌的抗癌活性。
J Biol Chem. 2021 Dec;297(6):101353. doi: 10.1016/j.jbc.2021.101353. Epub 2021 Oct 27.
10
Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor.一种双环肽基泛Ras抑制剂的发现。
J Med Chem. 2021 Sep 9;64(17):13038-13053. doi: 10.1021/acs.jmedchem.1c01130. Epub 2021 Aug 20.

本文引用的文献

1
Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides.通过环状肽阻断Ras效应物相互作用来抑制Ras信号传导。
Angew Chem Int Ed Engl. 2015 Jun 22;54(26):7602-6. doi: 10.1002/anie.201502763. Epub 2015 May 7.
2
KRAS as a Therapeutic Target.KRAS作为一种治疗靶点。
Clin Cancer Res. 2015 Apr 15;21(8):1797-801. doi: 10.1158/1078-0432.CCR-14-2662.
3
Dragging ras back in the ring.将 ras 拖回拳击场。
Cancer Cell. 2014 Mar 17;25(3):272-81. doi: 10.1016/j.ccr.2014.02.017.
4
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.K-Ras(G12C) 抑制剂变构控制 GTP 亲和力和效应物相互作用。
Nature. 2013 Nov 28;503(7477):548-51. doi: 10.1038/nature12796. Epub 2013 Nov 20.
5
Recombinant probes for visualizing endogenous synaptic proteins in living neurons.用于在活神经元中可视化内源性突触蛋白的重组探针。
Neuron. 2013 Jun 19;78(6):971-85. doi: 10.1016/j.neuron.2013.04.017.
6
Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery.mRNA 展示筛选的抗体模拟配体靶向树突状细胞特异性 C 型凝集素用于树突状细胞导向的抗原递呈。
ACS Chem Biol. 2013 May 17;8(5):967-77. doi: 10.1021/cb300680c. Epub 2013 Mar 8.
7
Single-round, multiplexed antibody mimetic design through mRNA display.通过 mRNA 展示技术进行单轮、多重抗体模拟设计。
Angew Chem Int Ed Engl. 2012 Dec 7;51(50):12449-53. doi: 10.1002/anie.201207005. Epub 2012 Nov 4.
8
RAS oncogenes: weaving a tumorigenic web.RAS 癌基因:编织致癌网络。
Nat Rev Cancer. 2011 Oct 13;11(11):761-74. doi: 10.1038/nrc3106.
9
Rapid mRNA-display selection of an IL-6 inhibitor using continuous-flow magnetic separation.利用连续流磁分离技术快速筛选白细胞介素 6 抑制剂。
Angew Chem Int Ed Engl. 2011 Aug 29;50(36):8295-8. doi: 10.1002/anie.201101149. Epub 2011 Jul 14.
10
Adnectins: engineered target-binding protein therapeutics.衔接蛋白:工程化的靶向结合蛋白治疗药物。
Protein Eng Des Sel. 2011 Jan;24(1-2):3-9. doi: 10.1093/protein/gzq097. Epub 2010 Nov 10.